Humira (Adalimumab) Denied by Insurance: How to Appeal

Humira (adalimumab) is one of the most prescribed biologic medications in the world, used to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and several other inflammatory conditions. Despite its widespread use and FDA approval across multiple indications, insurance denials for Humira remain extremely common — leaving patients in pain and without access to a therapy their doctor has determined is medically necessary.

Why Insurance Companies Deny Humira

Step therapy requirements are the most frequent reason for Humira denials. Most insurers require patients to try and fail cheaper medications before approving a biologic like Humira. For rheumatoid arthritis, this typically means first trying methotrexate (MTX), sulfasalazine (SSZ), or hydroxychloroquine. For Crohn's disease, insurers often require a trial of corticosteroids or immunomodulators. The step therapy protocol can delay access to Humira by months, during which your condition may worsen significantly.

Biosimilar switching is an increasingly common denial trigger. As biosimilars of adalimumab (such as Hadlima, Hyrimoz, Cyltezo, and others) have entered the market, some insurers now only cover those products rather than brand-name Humira, or they require patients currently stable on Humira to switch. If your insurer has moved Humira off formulary entirely in favor of a biosimilar, your doctor will need to document why switching could destabilize your condition.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization (PA) is required by virtually every insurer for Humira. Without an approved PA, your pharmacy will reject the prescription. PA requirements typically include diagnosis confirmation, documentation of failed prior therapies, lab values, and clinical notes showing active disease.

Tier placement affects cost-sharing even when coverage is approved. Humira typically falls in a specialty drug tier with coinsurance rates of 20–40%, which can mean thousands of dollars out of pocket per month even with insurance.

How to Appeal a Humira Denial

A successful Humira appeal requires specific, clinical documentation. Here is what to gather and emphasize:

Document prior therapy failure. Your appeal letter must clearly describe every medication you tried before Humira, how long you took it, what dose you reached, and why it failed — whether due to inadequate efficacy or intolerable side effects. Generic statements are not enough. Include specific symptom scores, lab values (such as CRP, ESR, or SED rate for RA), and physician notes from those treatment periods.

Include objective disease activity scores. For RA, provide DAS28 or CDAI scores showing active disease despite prior treatment. For Crohn's, use Harvey-Bradshaw Index or Crohn's Disease Activity Index scores. For psoriasis, include PASI or BSA scores. For psoriatic arthritis, provide ACR response criteria. Insurers are required to review quantifiable clinical evidence when making medical necessity determinations.

Obtain a letter of medical necessity. Your rheumatologist, gastroenterologist, or dermatologist should write a detailed letter explaining why Humira is the appropriate treatment for your specific case, why biosimilar substitution would be inappropriate (if applicable), and what clinical harm further delay would cause.

Request peer-to-peer review. Your prescribing physician can request a direct call with the insurer's medical reviewer. This conversation frequently results in approvals that written appeals alone do not achieve. Specialists are often more persuasive than paperwork.

Cite clinical guidelines. The ACR, AGA, and AAD publish treatment guidelines that support biologic use after conventional therapy failure. Referencing these guidelines in your appeal strengthens your case by showing the insurer that your doctor's recommendation aligns with evidence-based standards of care.

File an expedited appeal if your condition is urgent. If delay would cause serious harm — such as a Crohn's flare requiring hospitalization — you may be entitled to an expedited internal appeal decision within 72 hours.

What to Do If Your Appeal Is Denied

If your internal appeal is denied, escalate to an independent External Independent Review: Complete Guide" class="auto-link">external review. Under the ACA, insurers must provide access to an IROs) Explained" class="auto-link">independent review organization (IRO) for denied medical necessity claims. External reviewers overturn insurer decisions at surprisingly high rates.

File a complaint with your state insurance commissioner, especially if you believe the insurer violated step therapy override laws. Many states now have laws requiring insurers to grant step therapy exceptions when a patient's physician documents that the required first-line drug is contraindicated, previously failed, or not appropriate.

Patient Assistance While You Appeal

AbbVie offers the myAbbVie Assist program for patients who are uninsured or whose insurance does not cover Humira. Income-based free product may be available. Contact myAbbVie Assist at 1-800-222-6885 or visit abbvie.com/myabbvieassist. AbbVie also offers copay assistance cards for commercially insured patients that can dramatically reduce out-of-pocket costs while your appeal proceeds.

Do not stop taking Humira or delay starting it without discussing alternatives with your doctor. Gaps in biologic therapy can allow disease to progress and may even affect your ability to restart the drug effectively.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?